Business & FinanceTop StoryTop StoryLatest News
Gland Pharma Q2FY27 Results: Net Profit Rises 58% to ₹290.75 Crore
Sentiment: PositiveHigh Priority
What Happened?
Gland Pharma reported a 58.29% increase in consolidated net profit to ₹290.75 crore for Q2FY27, driven by strong business execution. Revenue rose to ₹1,833.58 crore from ₹1,486.87 crore a year ago.
Key points
- Net profit increased to ₹290.75 crore from ₹183.68 crore year-on-year.
- Revenue from operations rose to ₹1,833.58 crore in Q2FY27.
- Total expenses increased to ₹1,471.69 crore from ₹1,287.12 crore a year earlier.
- Four new molecules launched in the US: Sugammadex, Erythromycin, Fluorouracil, and Atropine sulfate.
- CDMO business grew by 31% year-on-year.
- Shares rose by 0.70% to ₹3,169.4 on the BSE.
Key insights
- The growth in net profit may attract more investors to Gland Pharma.
- Continued investment in manufacturing could enhance Gland Pharma's competitive edge.
- The launch of new molecules may expand Gland Pharma's market share in the US.
Why it matters
The strong profit growth indicates Gland Pharma's effective business strategies and market position.
Tags
Entities
Gland Pharma· CompanySrinivas Sadu· Person
Source
Business Standard
